Protalix BioTherapeutics, Inc. - Common Shares (PLX)

CUSIP: 74365A309

Q4 2022 13F Holders as of 31 Dec 2022

Holder snapshot 7 signals
Share change
+20,133
Put/Call ratio
20%
SEC-reported price per share
$1.37
Number of holders
26
Value change
+$111,553
Number of buys
12
Open additional details 1 more signal available
Number of sells
7
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
79,957,519

Security key

74365A309

Report period

Q4 2022

Institutions

26

Top holders

10

Ownership snapshot

Top reported holders of PLX - Protalix BioTherapeutics, Inc. - Common Shares (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Dexcel Pharma Technologie...
Disclosed value leader
Dexcel Pharma Technologie...
Comparable rows
0/15
Latest evidence
30 Sep 2022
3/4/5 13F Highest disclosed value: $5,128,613 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Dexcel Pharma Technologies Ltd. has the largest disclosed position value at $5.13M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Dexcel Pharma Technologies Ltd.'s linked filing trail.
Disclosed position value Top 5
Dexcel Pharma Technologies Ltd. $5.13M
HIGHBRIDGE CAPITAL MANAGEMENT LLC $2.51M
MEITAV INVESTMENT HOUSE LTD $256K
SUSQUEHANNA INTERNATIONAL GROUP, LLP $231K
BRIDGEWAY CAPITAL MANAGEMENT, LLC $139K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Dexcel Pharma Technologies Ltd.
3/4/5
10%+ Owner
—
denominator unverified
$5,128,613
3,637,314 shares
— 02 Jun 2021
HIGHBRIDGE CAPITAL MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$2,513,000
2,413,487 shares
— 30 Sep 2022
MEITAV INVESTMENT HOUSE LTD
13F
Company
13F
—
denominator unverified
$256,000
244,332 shares
— 30 Sep 2022
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
13F
—
denominator unverified
$231,000
222,261 shares
— 30 Sep 2022
BRIDGEWAY CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$139,000
133,790 shares
— 30 Sep 2022
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
—
denominator unverified
$122,000
117,200 shares
— 30 Sep 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
26
Shares
3,567,822
Rows available
26
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders
26
Q4 2022 holders
26
Holder diff
0
Investor Q3 2022 Shares Q4 2022 Shares Share Diff Share Chg % Q3 2022 value Q4 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .